GlaxoSmithKline PLC
LSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
LSE:GSK
Watchlist
Price: 1 342 GBX 2.48% Market Closed
Market Cap: 54.7B GBX
Have any thoughts about
GlaxoSmithKline PLC?
Write Note

GlaxoSmithKline PLC
Effect of Foreign Exchange Rates

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

GlaxoSmithKline PLC
Effect of Foreign Exchange Rates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Effect of Foreign Exchange Rates CAGR 3Y CAGR 5Y CAGR 10Y
GlaxoSmithKline PLC
LSE:GSK
Effect of Foreign Exchange Rates
-ÂŁ38m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
17%
AstraZeneca PLC
LSE:AZN
Effect of Foreign Exchange Rates
-$65m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Verona Pharma PLC
NASDAQ:VRNA
Effect of Foreign Exchange Rates
$1.9m
CAGR 3-Years
40%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Effect of Foreign Exchange Rates
$1m
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Effect of Foreign Exchange Rates
-$9m
CAGR 3-Years
3%
CAGR 5-Years
-18%
CAGR 10-Years
-16%
Dechra Pharmaceuticals PLC
LSE:DPH
Effect of Foreign Exchange Rates
-ÂŁ400k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GlaxoSmithKline PLC
Glance View

Market Cap
54.7B GBX
Industry
Pharmaceuticals

GlaxoSmithKline PLC (GSK) is a global healthcare giant rooted in extensive research and development, dedicated to improving the health and well-being of people around the world. Founded in 2000 through a merger of Glaxo Wellcome and SmithKline Beecham, GSK has built a diverse portfolio that spans pharmaceuticals, vaccines, and consumer healthcare. With a strong emphasis on innovation, GSK invests heavily in R&D, focusing on tackling significant health challenges such as infectious diseases, oncology, and respiratory ailments. The company’s robust pipeline showcases its commitment to advancing medical science, promising both potential breakthroughs for patients and lucrative prospects for investors. In recent years, GSK has taken strategic steps to simplify its business model, including the spin-off of its consumer healthcare segment into a separate entity. This maneuver has allowed GSK to concentrate on its core pharmaceutical and vaccine operations, optimizing its resources towards high-growth areas. As the world faces ongoing health crises and the demand for vaccines, particularly following the COVID-19 pandemic, GSK is well-positioned to capitalize on its innovation and solid market presence. For investors, GSK's balance sheet reflects a stable dividend, attractive growth prospects, and a commitment to sustainable practices, fostering confidence that it remains a compelling choice in the ever-evolving healthcare landscape.

GSK Intrinsic Value
2 400.47 GBX
Undervaluation 44%
Intrinsic Value
Price

See Also

What is GlaxoSmithKline PLC's Effect of Foreign Exchange Rates?
Effect of Foreign Exchange Rates
-38m GBP

Based on the financial report for Jun 30, 2024, GlaxoSmithKline PLC's Effect of Foreign Exchange Rates amounts to -38m GBP.

What is GlaxoSmithKline PLC's Effect of Foreign Exchange Rates growth rate?
Effect of Foreign Exchange Rates CAGR 10Y
17%

Over the last year, the Effect of Foreign Exchange Rates growth was -100%. The average annual Effect of Foreign Exchange Rates growth rates for GlaxoSmithKline PLC have been 28% over the past three years , and 17% over the past ten years .

Back to Top